Upregulation of RASAL2 promotes proliferation and metastasis, and is targeted by miR-203 in hepatocellular carcinoma

Molecular Medicine Reports
Jian-Feng FangShusen Zheng

Abstract

RAS protein activator like 2 (RASAL2) has been reported to be dysregulated in various types of cancer. It has previously been demonstrated that RASAL2 is hypomethylated in hepatocellular carcinoma (HCC). However, the expression pattern of RASAL2 and its potential role in HCC remain to be elucidated. The present study demonstrated that the expression of RASAL2 was upregulated in HCC tissues, compared with in normal liver tissues, by using immunohistochemistry. In addition, Cell Counting Kit-8 assay and invasion assay revealed that knockdown of RASAL2 inhibited the growth and invasion of HCC cells. Western blotting results indicated that the inhibition of RASAL2 reduced the levels of phosphorylated-AKT. Notably, RASAL2 was observed to be a direct target of miR-203 in HCC in luciferase activity assays. Furthermore, overexpression of miR-203 exhibited a similar effect to RASAL2 knockdown in HCC cells. These results indicated that RASAL2 serves a tumor oncogenic role in HCC and may be considered a potential target in HCC.

References

Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Dec 12, 2003·Lancet·Josep M LlovetJordi Bruix
Dec 30, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Fikret SahinMichael Torbenson
Feb 5, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Aurelia NoskeKai Wiechen
Feb 13, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Christopher D MannDavid P Berry
May 28, 2008·Oncogene·F E BleekerA Bardelli
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sean F AltekruseMarsha E Reichman
Mar 6, 2009·Nature Reviews. Cancer·Milena S NicolosoGeorge A Calin
Jun 16, 2009·Cell·Scott ValastyanRobert A Weinberg
Jul 28, 2009·Annual Review of Medicine·Ramiro GarzonCarlo M Croce
Feb 23, 2012·Lancet·Alejandro FornerJordi Bruix
Jun 12, 2012·The American Journal of Pathology·Adrienne WeeksJames T Rutka
Aug 14, 2012·Cell Biochemistry and Function·Wang WeiZhao Jisheng
Oct 17, 2012·CA: a Cancer Journal for Clinicians·Mary Maluccio, Anne Covey
Mar 8, 2013·Current Opinion in Genetics & Development·Gianpiero Di Leva, Carlo M Croce
Apr 26, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Barbara StefanskaMoshe Szyf
Nov 11, 2014·The Journal of Clinical Investigation·Min FengQiang Yu
Jun 14, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Naitao WangWei-Qiang Gao

Related Concepts

MIRN203 microRNA, human
RASAL2 protein, human
Carrier Proteins
Liver Carcinoma
Malignant Neoplasm of Liver
Neoplasm Metastasis
Neoplasm Proteins
RNA, Neoplasm
Receptor Up-Regulation
Gene Expression Regulation, Neoplastic

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Related Papers

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Donghua GengJingang Liu
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Qing-jun LiKefeng Dou
© 2021 Meta ULC. All rights reserved